There is no single “best” prescription medicine for memory loss. The most effective option depends on the cause of memory loss, how far it has progressed, and whether the goal is managing symptoms or slowing the underlying disease. For Alzheimer’s disease, which is the most common cause of progressive memory loss, the combination of donepezil and memantine consistently outperforms either drug alone across measures of cognition, daily functioning, and behavioral symptoms in clinical trials.
How Memory Medications Work
Most prescription drugs for memory loss target one of two chemical systems in the brain. The first group, called cholinesterase inhibitors, prevents the breakdown of acetylcholine, a chemical messenger essential for learning and memory. In Alzheimer’s disease, the brain cells that produce acetylcholine are damaged and gradually lost, so keeping whatever acetylcholine remains active for longer can help preserve thinking ability. Donepezil, rivastigmine, and galantamine all work this way.
The second approach targets glutamate, the brain’s main excitatory chemical. In Alzheimer’s, nerve cells become chronically overstimulated by glutamate, which damages and eventually kills them. Memantine blocks this overstimulation while still allowing normal signaling. It’s approved for moderate to severe Alzheimer’s and is sometimes used off-label for milder stages.
Medications for Mild to Moderate Alzheimer’s
Donepezil, galantamine, and rivastigmine are all FDA-approved for mild to moderate Alzheimer’s symptoms. Of these, donepezil is the most widely prescribed, partly because it covers the broadest range of disease stages (mild through severe) and is taken once daily. Rivastigmine is available as a skin patch, which can be helpful for people who have trouble swallowing pills or experience stomach-related side effects with oral medications. Galantamine has a slightly different mechanism: in addition to preserving acetylcholine, it also stimulates certain receptors to release more of it.
None of these drugs reverse memory loss. What they can do is temporarily stabilize or modestly improve cognitive function for a period of months to a few years. The effects are real but subtle. Many caregivers notice the difference most clearly if the medication is stopped and symptoms worsen.
Medications for Moderate to Severe Stages
When Alzheimer’s progresses to the moderate or severe stage, memantine becomes an option, either alone or combined with donepezil. The combination is available as a single capsule. A network meta-analysis published in Brain and Behavior compared donepezil alone, memantine alone, and the combination across four dimensions: cognition, overall clinical status, daily activities, and behavioral symptoms. The combination ranked first in every category. On a standardized cognitive test, patients on combination therapy improved significantly more than those on placebo, and both individual drugs fell in between.
One trade-off: the combination had lower “acceptability” than either drug alone, meaning more patients discontinued it, likely due to a higher side effect burden. This is a conversation worth having with a prescribing doctor, since the cognitive benefits need to be weighed against tolerability for each individual.
Newer Disease-Modifying Treatments
A newer class of drugs takes a fundamentally different approach. Instead of managing symptoms, lecanemab and donanemab target amyloid plaques, the sticky protein clumps that build up in the brains of people with Alzheimer’s. Both are FDA-approved, but only for people with mild cognitive impairment or mild dementia who have confirmed amyloid buildup in their brains.
These drugs are given as intravenous infusions. Donanemab is administered every four weeks. Before starting either medication, patients are tested for a genetic variant called ApoE ε4, which increases the risk of a side effect called ARIA, a type of brain swelling or microbleeding visible on MRI scans. Regular brain imaging is required during treatment to monitor for this.
These immunotherapies slow cognitive decline rather than stop it entirely. They represent the first treatments that address one of the biological causes of Alzheimer’s rather than just its symptoms, but they are not appropriate for everyone and carry risks that the older symptom-management drugs do not.
What About Mild Cognitive Impairment?
Many people searching for memory loss medications are in an earlier stage, where forgetfulness is noticeable but daily life is still manageable. This is often called mild cognitive impairment, or MCI. The American Academy of Neurology’s practice guidelines are clear on this point: no FDA-approved medications exist for MCI, and no high-quality, long-term studies have shown that any drug reliably improves cognition or delays progression at this stage.
Some doctors do prescribe cholinesterase inhibitors off-label for MCI, but the guidelines state they should first discuss the lack of supporting evidence. The newer amyloid-targeting drugs (lecanemab and donanemab) are the first to include MCI patients in their approved indications, but only when amyloid pathology has been confirmed through a PET scan or spinal fluid test.
Common Side Effects
In a study of patients receiving anti-dementia drugs at home, about 21% experienced side effects significant enough to be documented. The most common were agitation and insomnia (45% of those with side effects), nausea, vomiting, or diarrhea (34%), and hallucinations or delusions (21%). Cholinesterase inhibitors are the primary source of gastrointestinal symptoms, while memantine more commonly causes dizziness and lightheadedness.
Starting at the lowest dose and increasing gradually over at least four weeks helps minimize early side effects, particularly the nausea that often accompanies cholinesterase inhibitors. Higher doses of donepezil are associated with significantly more stomach problems. Patients taking 10 or more medications daily had a higher risk of adverse events, as did those whose prescriptions were not regularly reviewed for effectiveness. This highlights the importance of ongoing reassessment rather than simply continuing a medication indefinitely.
Memory Loss From Other Causes
Not all memory loss is Alzheimer’s. Lewy body dementia, which also causes visual hallucinations and movement problems similar to Parkinson’s disease, is sometimes treated with the same cholinesterase inhibitors, particularly rivastigmine and donepezil. However, people with Lewy body dementia can be unusually sensitive to certain medications, so treatment requires careful monitoring. Some standard Alzheimer’s or Parkinson’s drugs are poorly tolerated in this population.
For vascular dementia, caused by reduced blood flow to the brain from strokes or small vessel disease, there are no FDA-approved medications specifically for memory symptoms. Cholinesterase inhibitors and memantine are sometimes used off-label, but the primary treatment strategy focuses on managing the underlying vascular risk factors: blood pressure, cholesterol, diabetes, and preventing further strokes.
Memory problems caused by depression, thyroid disorders, vitamin deficiencies, sleep apnea, or medication side effects often improve substantially when the underlying condition is treated. These reversible causes are worth ruling out before starting any dementia-specific medication, since the drugs carry side effects and are designed for progressive neurodegenerative conditions, not temporary cognitive changes.